Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00093964 · ClinicalTrials.gov registry record · Phase 2
Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
A Phase 2 study of Glioblastoma Multiforme, sponsored by EMD Serono.
- Completed
- Registry status
- Phase 2
- Development phase
- 81
- Enrollment target
- 17
- Study locations
NCT00093964: Completed Phase 2 study of Glioblastoma Multiforme, sponsored by EMD Serono.
NCT00093964 is a Phase 2 study of Glioblastoma Multiforme that has completed, run by EMD Serono. The registered enrollment target is 81 participants, below the 96-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (16% lower). The trial reports 17 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00093964, a Phase 2 study of Glioblastoma Multiforme, has completed, sponsored by EMD Serono.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 81 participants
- Enrollment target
- 17
- Study locations
Study Summary
This study will investigate clinical activity, safety, and tolerability of the anti-angiogenic compound cilengitide (EMD 121974) in the treatment of first recurrence of glioblastoma multiforme (GBM).
Primary Outcome
Progression-free survival was defined as subjects who survived greater than or equal to (\>=) 180 days without disease progression. Disease progression was assessed as per independent central blinded radiology assessment.
Conditions Studied
Interventions
- DRUG Cilengitide 500 mg
- DRUG Cilengitide 2000 mg
Study Locations (17)
Massachusetts
- Massachusetts General Hospital - Boston
- University of Massachusetts - Worcester
Texas
- Baylor University Medical Center at Dallas - Dallas
- University of Texas MD Anderson Cancer Center - Houston
Alabama
- University of Alabama at Birmingham - Birmingham
Arizona
- Barrow Neurological Institute - Phoenix
California
- UCLA Medical Center - Los Angeles
Colorado
- Denise Damek - Aurora
Illinois
- Northwestern University - Chicago
Indiana
- Indiana University Medical Center - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2004-10-13 |
| Est. Completion | 2010-10-21 |
| Phase | Phase 2 |
What the finished NCT00093964 record still lists
NCT00093964 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 81 participants, a relatively small participant target, below the 96-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (16% lower).
The record links to 1 condition, with Glioblastoma Multiforme appearing as the primary indexed condition, and to 2 interventions - of which Cilengitide 500 mg is the first listed.
NCT00093964 lists 17 locations in 15 states (Massachusetts, Texas, Alabama).
Frequently Asked Questions
What is clinical trial NCT00093964 about?
NCT00093964 is a clinical study titled "Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)". This study will investigate clinical activity, safety, and tolerability of the anti-angiogenic compound cilengitide (EMD 121974) in the treatment of first recurrence of glioblastoma multiforme (GBM).
What is the current status of trial NCT00093964?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 81 participants. The study started on 2004-10-13. Estimated completion is 2010-10-21.
What conditions does trial NCT00093964 study?
This clinical trial studies the following conditions: Glioblastoma Multiforme.
What interventions are being tested in trial NCT00093964?
The interventions under investigation include: Cilengitide 500 mg (DRUG), Cilengitide 2000 mg (DRUG).
Who is sponsoring clinical trial NCT00093964?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00093964 being conducted?
This trial has 17 study locations across Alabama, Arizona, California, Colorado, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma Multiforme
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00093964's enrollment target sits among peer trials
81 23rd of 88 higher than 66 of 88 other Glioblastoma Multiforme trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma Multiforme trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)
RECRUITING · Phase 2
-
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
RECRUITING · Phase 2
-
A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment
RECRUITING · Phase 2
-
Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
RECRUITING · Phase 2
-
Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04966481 · 81 participants · Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- NCT05109429 · 81 participants · NA
Developing a Clinical Outcome Assessment for Opioid Craving
- NCT05112601 · 81 participants · Phase 2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- NCT05305911 · 81 participants · Phase 2
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI